Welgene Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
May 11, 2021
Share
Welgene Biotech Co.,Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was TWD 48.310 million compared to TWD 91.764 million a year ago. Operating loss was TWD 4.659 million compared to operating Income of TWD 4.744 million a year ago. Net loss was TWD 5.532 million compared to net income of TWD 1.862 million a year ago. Basic loss per share was TWD 0.25 compared to basic earnings per share of TWD 0.09 a year ago.
WELGENE BIOTECH CO., LTD. is a Taiwan-based company mainly engaged in the provision of genetic testing services and products. The company focuses on deoxyribonucleic acid (DNA) microarray, Next Generation Sequencing and real-time quantitative polymerase chain reaction (PCR) and other testing technologies, which used in school research units, hospitals and biotech companies. The Company is also engaged in the trading of medical equipment. The company mainly operates in two business segments, including Biotechnology Testing segment and Equipment Trading segment. The Company mainly operates in Taiwan market.
WELGENE BIOTECH CO.,LTD. 
